March 13 Venaxis Inc said its
appendicitis test correctly predicted results in 97 percent of
patients in a clinical trial, sending its shares up 25 percent
in premarket trade.
The company said it expected to finalize its marketing
application and submit it to the U.S. Food and Drug
Administration in the next few weeks.
The rapid test, called APPY1, identifies patients who are at
low risk for appendicitis.
Venaxis's shares jumped 25 percent to $3.39 in trading
before the bell. They closed at $2.71 on the Nasdaq on
(Reporting by Esha Dey in Bangalore; Editing by Simon Jennings)